What is the recommended dose and route of administration for amikacin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Amikacin Dosing and Route of Administration

Amikacin should be administered intravenously (IV) or intramuscularly (IM) at a dose of 15 mg/kg once daily for adults, with a maximum of 1 gram per day, and 15-30 mg/kg once daily for children, with a maximum of 1 gram per day. 1, 2, 1

Standard Dosing Regimens

Adults

  • Standard dose: 15 mg/kg/day IV or IM, typically given as a single daily dose (5-7 days/week initially) 1, 2, 1
  • Maximum daily dose: 1 gram/day (some sources allow up to 1.5 g/day in heavier patients) 3
  • Alternative regimen: 7.5 mg/kg every 12 hours OR 5 mg/kg every 8 hours 3
  • Age adjustment: For patients >59 years, reduce to 10 mg/kg/day (750 mg maximum) 1, 2

Children

  • Standard dose: 15-30 mg/kg/day IV or IM as a single daily dose 1, 2, 1
  • Maximum: 1 gram/day 1, 2
  • Newborns: Loading dose of 10 mg/kg, followed by 7.5 mg/kg every 12 hours 3

Route of Administration

Both IV and IM routes are acceptable 1, 2, 1, 3. For IV administration:

  • Infuse over 30-60 minutes in adults 3
  • Infuse over 30-60 minutes in pediatric patients 3
  • Infuse over 1-2 hours in infants 3

Special Populations and Dosing Adjustments

Renal Impairment

Critical consideration: Amikacin clearance is almost exclusively renal, requiring mandatory dose adjustments 1, 2, 1. Two approaches are available:

  1. Extended interval dosing (preferred): Maintain the 12-15 mg/kg dose but reduce frequency to 2-3 times per week to leverage concentration-dependent bactericidal effects 1, 2

  2. Reduced dose at fixed intervals: Calculate maintenance dose proportional to creatinine clearance reduction 3

Practical adjustment: If creatinine clearance unavailable, multiply serum creatinine by 9 to determine dosing interval in hours (e.g., serum creatinine 2 mg/dL = dose every 18 hours) 3

Obesity

For markedly obese patients, use adjusted body weight: ideal body weight + 40% of excess weight 4

  • Male IBW (kg) = 50 + (2.3 × height in cm above 152.4)/2.54
  • Female IBW (kg) = 45.5 + (2.3 × height in cm above 152.4)/2.54

Specific Infections

Tuberculosis/NTM: 15 mg/kg/day (maximum 1 g) initially daily, then reduce to 2-3 times weekly after 2-4 months or culture conversion 1, 2, 1

Plague treatment: 15-20 mg/kg every 24 hours IV or IM 5

Uncomplicated UTI: 250 mg twice daily may be sufficient 3

Carbapenem-resistant Enterobacterales: 15 mg/kg/day IV once daily 6

Therapeutic Drug Monitoring

Essential for safety and efficacy 1, 2, 1:

Target Levels

  • Peak concentration: 25-35 mg/L (daily dosing) or 65-80 mg/L (three times weekly dosing) 4
  • Trough concentration: <5 mg/L (ideally <2.5 mg/L) 4, 3
  • Avoid: Peak >35 mcg/mL and trough >10 mcg/mL 3

Monitoring Schedule

  • Obtain peak level in first week 4
  • Trough levels weekly for 4 weeks, then can reduce to biweekly when stable 4
  • Peak sample: 60-120 minutes after infusion ends 4
  • Trough sample: immediately before next dose 4

Safety Monitoring

Baseline Assessment

  • Audiogram, vestibular testing, Romberg testing 1, 2, 1
  • Serum creatinine 1, 2, 1

Ongoing Monitoring

  • Renal function: Twice weekly during month 1, weekly during month 2, then biweekly 4
  • Auditory/vestibular symptoms: Monthly questioning 1, 2, 1
  • Repeat audiogram if symptoms of ototoxicity develop 1, 2, 1

Critical Safety Considerations

Nephrotoxicity: Amikacin may be more nephrotoxic than streptomycin 1, 2. Risk increases with:

  • Elevated baseline creatinine 1, 2
  • Higher cumulative doses 1, 2
  • Concomitant nephrotoxic agents (especially vancomycin) 1, 2

Ototoxicity: Primarily causes hearing loss (less vestibular dysfunction than streptomycin) 1, 2. Risk increases with:

  • Prolonged treatment duration 1, 2
  • Higher doses 1, 2
  • Concurrent diuretic use 1, 2
  • Advanced age 1, 2

Pregnancy: Contraindicated due to risk of fetal nephrotoxicity and congenital hearing loss 1, 2, 1

Treatment Duration

  • Standard: 7-10 days 3
  • Tuberculosis/NTM: Continue for 2-4 months or until culture conversion, then may reduce frequency 1, 2
  • Plague: 10-14 days 5
  • If treatment beyond 10 days is required, re-evaluate necessity and intensify monitoring 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.